Redrado M - Search Results

1

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma.

Valencia K, Sainz C, Bértolo C, de Biurrun G, Agorreta J, Azpilikueta A, Larrayoz M, Bosco G, Zandueta C, Redrado M, Redín E, Exposito F, Serrano D, Echepare M, Ajona D, Melero I, Pio R, Thomas R, Calvo A, Montuenga LM. Valencia K, et al. Among authors: redrado m. Dis Model Mech. 2022 Jan 1;15(1):dmm049137. doi: 10.1242/dmm.049137. Epub 2022 Jan 31. Dis Model Mech. 2022. PMID: 34870316 Free PMC article.

2

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer.

Diaz R, Nguewa PA, Diaz-Gonzalez JA, Hamel E, Gonzalez-Moreno O, Catena R, Serrano D, Redrado M, Sherris D, Calvo A. Diaz R, et al. Among authors: redrado m. Br J Cancer. 2009 Mar 24;100(6):932-40. doi: 10.1038/sj.bjc.6604938. Epub 2009 Feb 24. Br J Cancer. 2009. PMID: 19240717 Free PMC article.

3

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.

Diaz R, Nguewa PA, Parrondo R, Perez-Stable C, Manrique I, Redrado M, Catena R, Collantes M, Peñuelas I, Díaz-González JA, Calvo A. Diaz R, et al. Among authors: redrado m. BMC Cancer. 2010 May 11;10:188. doi: 10.1186/1471-2407-10-188. BMC Cancer. 2010. PMID: 20459769 Free PMC article.

4

Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage.

Gonzalez-Moreno O, Boque N, Redrado M, Milagro F, Campion J, Endermann T, Takahashi K, Saito Y, Catena R, Schomburg L, Calvo A. Gonzalez-Moreno O, et al. Among authors: redrado m. Prostate. 2011 Jun 1;71(8):824-34. doi: 10.1002/pros.21298. Epub 2010 Nov 17. Prostate. 2011. PMID: 21456065

5

Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance.

Ponz-Sarvisé M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, Pio R, Behrens C, Wistuba II, García-Franco CE, García-Foncillas J, Montuenga LM, Calvo A, Gil-Bazo I. Ponz-Sarvisé M, et al. Among authors: redrado m. Clin Cancer Res. 2011 Jun 15;17(12):4155-66. doi: 10.1158/1078-0432.CCR-10-3381. Epub 2011 May 3. Clin Cancer Res. 2011. PMID: 21540238

6

Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.

Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, Gonzalez A, Rodriguez I, Bolaños E, Hervás-Stubbs S, Perez-Calvo J, Benito A, Peñuelas I, Vigil C, Richter J, Martinez-Forero I, Melero I. Alfaro C, et al. Among authors: redrado m. J Immunol. 2011 Dec 1;187(11):6130-42. doi: 10.4049/jimmunol.1102209. Epub 2011 Nov 2. J Immunol. 2011. PMID: 22048768 Free article. Clinical Trial.

7

The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.

Ibáñez E, Agliano A, Prior C, Nguewa P, Redrado M, González-Zubeldia I, Plano D, Palop JA, Sanmartín C, Calvo A. Ibáñez E, et al. Among authors: redrado m. Curr Med Chem. 2012;19(18):3031-43. doi: 10.2174/092986712800672076. Curr Med Chem. 2012. PMID: 22455594

8

Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts.

Martin-Padura I, Marighetti P, Agliano A, Colombo F, Larzabal L, Redrado M, Bleau AM, Prior C, Bertolini F, Calvo A. Martin-Padura I, et al. Among authors: redrado m. Lab Invest. 2012 Jul;92(7):952-66. doi: 10.1038/labinvest.2012.65. Epub 2012 Apr 30. Lab Invest. 2012. PMID: 22546866 Free article.

9

Epithelial to mesenchymal transition and cancer stem cell phenotypes leading to liver metastasis are abrogated by the novel TGFβ1-targeting peptides P17 and P144.

Zubeldia IG, Bleau AM, Redrado M, Serrano D, Agliano A, Gil-Puig C, Vidal-Vanaclocha F, Lecanda J, Calvo A. Zubeldia IG, et al. Among authors: redrado m. Exp Cell Res. 2013 Feb 1;319(3):12-22. doi: 10.1016/j.yexcr.2012.11.004. Epub 2012 Nov 12. Exp Cell Res. 2013. PMID: 23153552

10

Spatial-temporal protein expression of inhibitor of differentiation-1 (Id1) during fetal embryogenesis and in different mouse and human cancer types.

Redrado M, Bodegas E, Villaro AC, Nguewa PA, Lopez I, Gil-Bazo I, Calvo A. Redrado M, et al. Histol Histopathol. 2013 Aug;28(8):1029-40. doi: 10.14670/HH-28.1029. Epub 2013 Apr 5. Histol Histopathol. 2013. PMID: 23558671

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43 results

Search Page

Filters